This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NI 105
Description: NI-105 is an antibody targeted against alpha-synuclein.
In December 2010, Biogen Idec and Neurimmune Holding AG announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43. Biogen Idec will make an initial payment of $32.5 million and up to $395 million in contingent payments.
Biogen Idec will be responsible for the development of the pre-clinical candidates and the commercialization of all products. Neurimmune will be responsible for additional scientific activities with respect to the lead candidates as well as the discovery of back-up candidates, utilizing its Reverse Translational Medicine technology platform. Neurimmune retains the right to use its platform for creating therapeutic antibody products outside the scope of its agreement with Biogen Idec.
Partners: Neurimmune Holdings AG
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: